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Can prenylcysteines be exploited as ligands for 
mammalian multidrug-resistance transporters? 
Lynne M Hurwitz and Patrick J Casey 
The overexpression of specific transport proteins in the 
membrane of many cancer cells renders these cells 
resistant to many therapeutic drugs. Some lipid-modified 
cysteine compounds inhibit one drug-transporting protein, 
indicating the potential of developing such compounds as 
therapeutic agents. 
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not fared well because the compounds cause significant 
side effects [S]. Novel inhibitors that are highly specific for 
the cell-surface transporters are no\v needed in order to 
OL ercome the drug-resistant phenotypes. In this article, ~z’e 
address hou. cell-surFJce transporters confer drug resistance 
in neoplastic diseases. \Ye also discuss recent results from 
our laboratory concerning ;I novel class of ligands directed 
against the transporters, and the potential use of these 
ligands to prc\.ent drug resistance. 
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Introduction 
‘I’hc presence of drug-resistant neoplastic phenotypes, 
partictllarl~ those that arc resistant to multiple classes of 
I’h;iriii”cotheraI’cutics. is a significant problem in mcdi- 
cinc [I]. ‘fhese phenotypes render standard medical treat- 
mcnts incffccti\e and. as a result, ha\-e incresscd the rates 
of mort:llit) in patients who ha1.e such drug-resistant neo- 
plaslns. ‘l’hc resistance of tumor cells to distinct anticancer 
agents is bnonm to be mediated by several different mcch- 
anisms. ‘Ike abilit) of a neoplasm to escape the toxic 
effects of chemotherapy depends on the capwit) of the 
ncoplastic cells to rcdr~ce the effecti\-cness of chemothcra- 
pctltic drug\. ‘l’his has been shon n to occur by \-ariokls cel- 
lular mcchnnisms that can reduce the intracellular 
concentration of the drug. alter the intracellular target of 
the drug:. modif>- cellular repair mechanisms and/or alter 
the signalin,q pathn-ay that allon the cell to escape from 
apoptotlc death [2,3]. It is the first of these mechanisms, 
the reduction of the intracellular drug concentration, that 
uc will disu~ss here. 
‘I’lie resistance of cancer cells to a wide 1 arietl of therapcu- 
tics deri\xxi from natural products is one particularly prel’a- 
lent type of rcsistancc, termed multidrug resistance 
(LIDR). It is generally charactcrizcd b>- the o\.erexpression 
of cell-surface transporters that acti\.cly transport the drug 
out of the cells [&A]. Rcscarch in a number of lahoratorics 
01 cr the past decade has led to the identification of at least 
tuo distinct transporters that are in\ol\.ed in this process 
and to sc\wal theories about ho\v multidrug resistance 
arises. :\s ;I result of these studies. pharmacological inter- 
\ cntion to OL ercome this problem is becoming a real possi- 
bility. Although sc\.cral classes of pharmacological agents 
ha\-c been dcl-clopcd that can re\.erse drug resistance in 
model ccl1 sytcms, clinical studies using these agents hal,e 
The transporters inlwlved in multidrug resistance belong to 
a family of transmembrane proteins termed ATPase 
binding cassette (ABC) proteins that are found in both 
prokaryotic and eukaryotic cells [6]. The basic structure of 
these proteins appears to have been conserved during el’o- 
lution. ZIembers of the ABC transporter family charac- 
teristicall>- contain a membrane-spanning region, a 
ligand-binding domain and an ATPase site (Figure la). The 
mcmhrane-spanning region is composed of hydrophobic 
amino acids and typicallv contains six transmemhrane 
spans. whereas the ATPase site and the l&and-binding site 
arc located on the c!-toplasmic domains of the protein. The 
characteristics of the ligand-binding site determine the sub- 
strate-binding specificit), and presumably the transport 
specificity of the protein. All these proteins transport 
substrates in an ~~I’Pase-dependent fashion [1,6]. 
T\vo cell-surfwe proteins belonging to the ABC transporter 
superfamil>- ha\,e been shwvn to function effectively in the 
removal of chemotherapeutic drugs from neoplastic cells. 
‘These two proteins. termed the type 1 multidrug-resis- 
tance transporter (klDR1, also known 3s P-glycoprotein) 
and the multidrug-resistance-associated protein (RIRP), 
were originally identified as proteins that were highly ovcr- 
expressed in mammalian cells that have the multidrug- 
resistant phenotype [7.8]. There are theorics about hov 
this increased expression of transporters de\ elops. For 
example, it has been proposed that the expression or 
amplification of genes encoding thcsc transporters is ;1 con- 
sequence of a cell’s response to chemotherapeutic agents. 
A second theory is that ;1 small population of the initial 
neoplastic cells has this phenotype of amplified cspression, 
and this population then expands after escaping the toxic 
effects of chemotherap)- [l]. In addition to their involve- 
ment in drug resistance in neoplasms, members of the 
ABC transporter family ha1.c also been implicated in the 
emergence of drug resistance in infectious diseases such as 
leishmaniasis and malaria. Elucidation of the role of these 
transporters in conferring drug resistance in these parasitic 
infections is still in its early stages [9.10]. 
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Figure 1 
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The transporters involved in drug resistance. (a) The topology of ABC 
transporters Red, membrane-spanning region; yellow, ATP-binding site; 
brown, potential ligand-binding site(s). (b) The proposed mechanisms 
of drug transport by MDRl and MRP. Substrates (purple) could interact 
with the transporter while the substrate is within the phospholipid 
bilayer (the so-called ‘vacuum phenomenon’) or after the substrate has 
entered the cytoplasm. In the latter case, the substrate may be directed 
to the transporter after binding an intracellular target (green). 
The exact mechanisms by which MDRl and MRP recog- 
nize and transport chemotherapeutic drugs are not yet 
clear, but the main routes through which it is thought to 
occur are shown in Figure lb. Drugs may interact with the 
transporter when they initially diffuse into the phospho- 
lipid bilayer, so that the drug never actually enters the 
cytoplasm of the cell. Alternatively, the drug may pass 
through the phospholipid bilayer, and the transporter 
could then expel the drug from the cytoplasm. In this situ- 
ation, an as-yet-unidentified cellular process may exist 
that directs the chemotherapeutic drug to the transporters 
after the drug has entered the cell. Another cellular mech- 
anism to reduce intracellular concentrations of certain 
cytotoxic drugs is for the cell to chemically modify the 
drug in such a way as to allow more efficient excretion of 
the drug; the most characterized modification of this type 
is the conjugation of a drug to glucathione by the enzyme 
glutathione-S-transferase [ 11,121. 
MDRl is by far the best-characterized transporter that is 
involved in drug resistance: amplified expression of 
MDRl has been implicated in conferring drug resistance 
in a wide variety of solid tumors as well as several types of 
leukemia and lymphoma [3,4]. Biochemical characteriza- 
tion of the protein showed that it requires both ATP and 
magnesium for its transport functions, and that ATP 
hydrolysis is essential for the transport process [4]. MDRl 
recognizes several chemotherapeutic drugs, including 
taxol, colchicine, vinblastine, doxorubicin, verapamil and 
cyclosporine A. The MDRl protein is expressed intrinsi- 
cally in several mammalian organs and tissues including 
the adrenal cortex, the proximal tubules of the kidney, the 
liver, the intestinal epithelium, the pancreatic ducts, spe- 
cific lymphocytes subclasses, the ov-arian follicles, and the 
capillaries of the testis and of the central nervous system 
[3]. This distribution of MDRl in normal human tissue 
has led to the proposition that hlDR1 has a physiological 
role in tissue detoxification. One recently elucidated 
potential function of hlDR1 depends on its ability to act 
as a ‘flippase’ that can translocate short chain lipids, such 
as phosphatidylcholine, across a membrane bilayer; this 
process is thought to be particularly important in the pro- 
duction of bile [13]. In addition, the disruption of the gene 
encoding the MDRl homolog in mice leads to damage of 
the nervous system early in life; this has been interpreted 
as indicating that MDRl acts as an essential toxin exporter 
along the blood-brain barrier [14]. 
MRP was first identified in 1992 in a lung-cancer cell line 
that was cultured in the presence of the chemotherapeutic 
agent adriamycin [8]. The MRP protein, which is some- 
what larger than MDRl, has been found to be overex- 
pressed in several solid tumor and leukemia cell lines. Like 
MDRl, it can transport chemotherapeutic drugs out of 
cells in an ATPase-dependent fashion. MDRl and MRP 
share limited specificity in drug recognition; MRP recog- 
nizes and transports etoposide, doxorubicin, daunorubicin, 
vincristine and epirubicine. [inlike MDRl, however, MRP 
does not interact with taxol, colchicine or lincristine with 
high specificity [15]. MRP is expressed under normal con- 
ditions in several mammalian cell types, most notably in 
the testis, the lung and peripheral blood mononuclear cells. 
Although the physiological functions of RIRP are currently 
unknown, this transporter has been shown to be important 
in human inflammatory reactions and in drug detoxifica- 
tion in the liver. Its role in inflammatory reactions has been 
inferred primarily from the finding that it can transport 
leukotriene C4, a known modulator of inflammatory reac- 
tions in humans [16]. The presence of jaundice in mice 
that have a mutation in a gene encoding a homolog of 
MRP led to the proposal that MRP is involved in drug 
Figure 2 
The structures of some lipid-modified cysteine 
compounds studied in association with 
multidrug transporters. Shown are the parent 
15 carbon farnesylcysteine (FC) and a variety 
of its derivatives. FCME, FCMA and FCA, 
which are the methyl ester, methyl amide and 
amide versions of FC respectively, are all 
substrates for MDRl, whereas their 
N-acetylated counterparts, AFCME, AFCMA 
and AFCA, are inhibitors of this transporter. 
For comparison, the structures of the 
prenylcysteine prototype (the yeast mating 
pheromone a factor) and S-decylglutathione 
are also shown. The thiol backbone is shown 
in red, the a-amino group and its 
modifications in pink and the a-carboxyl group 
and its modifications in green. 
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detoxification in the liver [ 171. hf RP has also been reported 
to transport S-decylglutathione [18], a compound that is 
similar in structure to the prenylcysteines that interact with 
hlDR1 (see below). Importantly, S-decylglutathione, like 
other identified transport substrates of hlRP, such as 
leukotriene c4 and glutathione-S-conjugates [19,20], has a 
net negative charge. In contrast, XlDRl has a preference 
for molecules that contain a positively charged group [3,4]. 
Eukaryotic cells can be made to produce high levels of 
hlDR1 and MRP through cDNA expression, allowing a 
detailed assessment of the interactions of the proteins 
with various compounds. The baker’s yeast S’~~~2~nromn~~s 
(et-mkiae has proven especially useful for examining the 
biological consequences of such interactions [Zl,ZZ], and 
high levels of expression of hIDR1 and hIRP in the Sf9 
insect cell system have allowed their biochemical proper- 
ties to be studied in detail [l&23,24]. Our laboratory has 
exploited the Sf9 expression system in particular. LJsing 
membranes from Sf9 cells that are infected with recombi- 
nant baculovirus encoding hlDR1, we have identified a 
new class of compounds that interact with hlDR1 - spe- 
cific lipid-modified cysteines, termed prenylcysteines. and 
their derivatives (2.5,26]. 
Prenylcysteines as ligands for multidrug transporters 
The covalent attachment of lipids to proteins is a process 
that occurs in essentially all cells. One of the most prevalent 
types of lipid modification in eukaryotic cells is prenylation, 
which involves the attachment of the 15 carbon farnesyl or 
20 carbon geranylgeranyl isoprenoid to cysteine residue(s) 
close to the carboxyl terminus of a protein. In most cases, 
the attached isoprenoid directs the protein to specific mem- 
branes within the cell and may also be involved in critical 
protein-protein interactions [27]. 
Studies on a yeast hlDR1 homolog, the Ste6 transporter 
protein, provided the first evidence for the potential of 
hlDR1 to function as a transporter of S-prenylated com- 
pounds. Steh is dedicated to the export of a specific 
mating pheromone peptide. a factor, from yeast cells that 
produce it [28]. Yeast cells lacking Steh are unable to mate 
because they cannot secrete a factor into the medium. 
Illature a factor contains a post-translationally modified 
carboxyl terminus in which the carboxy--terminal cysteine 
is S-prenylated by the farnesyl isoprenoid and methylated 
on the carboxyl group (Figure 2). This modified carboxy- 
terminal cysteine is a key structural feature that is recog- 
nized by Ste6, because yeast strains defective in 
carboxy-terminal cysteine processing are unable to 
produce an exportable a factor peptide (29,301. The 
finding that expression of hlDR1 in yeast cells lacking 
Ste6 could complement the mating defect and at least par- 
tially restore mating activity suggested that the similarities 
between hlDR1 and Steh extend to function as well as 
structure [Zl]. Later studies revealed that MRP could also 
function in this regard [ZZ]. Collectively, these studies 
implied that the modified carboxyl terminus of a factor 
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that is recognized by Steh is also involved in the specific 
interaction of a factor with both MDRl and MRP, and 
indicated that an understanding of the mechanisms 
involved in this process could lead to important insights 
into both drug transport and the physiological functions of 
MDRl and MRP 
We have found that specific prenylcysteine-containing 
compounds that correspond to the carboxy-terminal struc- 
tures of prenylated proteins interact with MDRl in a char- 
acteristic substrate-like way [ZS]. The structural features 
that are required for the specific interaction between 
prenylcysteine methyl esters and MDRl were strikingly 
similar to those required for the interaction of a factor with 
Ste6. In both cases, carboxyl methylation of the prcnyl- 
cysteine was essential, whereas neither transporter could 
apparently distinguish between a 15 carbon farnesyl or 20 
carbon geranylgeranyl isoprenoid on the sulfhydryl group 
of cysteine. Prenylcysteine-containing compounds have 
provided intriguing evidence for a potential physiological 
link between MDRl and prenylcysteine production in 
mammalian cells; they are also simple compounds that 
allow investigation of the essential structural elements 
that are recognized by MDR 1. 
Prenylcysteines containing a carboxyl derivative, such as a 
methyl ester. a methyl amide or an amide group (Figure Z), 
all activated the ATPase activity of MDRl in a similar 
fashion. In contrast, acetylation of the a-amino group of a 
prenylcysteine rendered the compound inactive. Interest- 
ingly, a doubly modified prenylcysteine that was both 
carboxy-methylated and amino-acetylated (i.e. AFCME; 
Figure 2) had activity that was consistent with it being an 
inhibitor of the transporter. In studies using MDRl-trans- 
fected human breast cancer cells, AFCME inhibited 
MDRl-mediated drug transport and enhanced the steady- 
state accumulation of vinblastine, colchicine or taxol [26]. 
Two other prenylcysteine analogs that are structurally 
related to AFCME, namely AFCA and AFCMA (Figure Z), 
also inhibited MDRl and restored drug accumulation in the 
cancer cells in an essentially identical fashion to AFCME 
(Figure 3) [26]. Consistent with these findings was the 
ability of the three compounds to inhibit the drug-stimu- 
lated ATPase activity of MDRl. Initial structure-activity 
analyses indicated that the most important features of these 
molecules for their inhibitory activities were the acetylated 
nitrogen atom and the lack of a negative charge on the 
a-carboxyl moiety [26]. These studies suggest a novel 
approach to designing inhibitors of MDRl-mediated drug 
efflux based on the structures of prenylcysteines. 
Although the specific prenylcysteine-based inhibitors of 
MDRl that have been developed to date are quite effective 
in vitro, they have many properties that limit their use in 
Gvo. The first limitation is their potency; the IC,,, values 
for inhibiting MDRl activity are in the range of 2040 FM, 
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The ability of a specific prenylcysteine, AFCMA, to restore accumulation 
of drug (in this case taxol) in human breast cancer cells overexpressing 
MDRl. For comparison, the typical level of taxol accumulation in the 
parental cell line that does not express significant levels of MDRl 
(drug-sensitive cells) is shown. See [261 for further details. 
which is certainly much higher than one would like for 
compounds to be used as therapeutic agents. The second 
concern is that, although the compounds are quite effective 
at restoring drug accumulation in MDRl-overexpressing 
tumor cells in short-term (i.e. 2-3 h) assays [26] (Figure 3), 
this effect is lost when the studies are conducted for longer 
time periods (L. Zhang and F!J.C., unpublished observa- 
tions). A likely explanation for this phenomenon is that the 
prenylcysteines are being metabolized in the cell; indeed, a 
novel enzyme capable of degrading prenylcysteines has 
recently been identified 1311. Medicinal chemists could 
help solve this problem, since it may be possible to design 
much more potent and stable analogs of the active prcnyl- 
cysteines by chemically modifying those portions of the 
molecules responsible for recognition by the multidrug 
transporters, namely the isoprenoid, a-carboxyl and 
cl-amino moieties. Given the flexibility of MDRl in ligand 
recognition, such an approach could well lead to the discov- 
ery of compounds with properties that make them more 
amenable for use as therapeutic agents. 
Prospects 
Overcoming multidrug resistance is a daunting problem. 
Pharmacological interventions are one approach to this 
problem, and the development of highly specific inhibitors 
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of the multidrug rransporters is essential for the SLICCCS~ of 
511ch dlerap): Information obtained from studies directed 
at understanding the physiological role of rhe multidrug 
wnsportcrs could led to the design of compounds with 
cnhmccd spwificity for these transporters. \\‘c feel that 
such information is indeed coming from an cx~uiiination of 
the role of lipid-modified qsteinc compounds as sub- 
suaTcs of die transporters. Although the interaction of 
prcnylc~ steinc compounds u ith \lKP still needs to bc 
charactcrixti, the present data indicate that pren) Icys- 
wines do interact u ith the tu.o ARC transporters that haw 
ken linked to drug resistance in cancer. \IDKl and 1\IKP 
(~ollccti~~cly rhe studies also highlight funcConvl similari- 
ties Ixween mcmlxrs of this transporux supcrfxnil\- that 
h21.c I cry limited structural homology-. 
\\c feel it shotild lx possible to exploit the chemical prop 
cl-tics of the no\ cl class of pren~lcysteine drug-resistance 
modtllaum to idcntif>- compounds that can rcvcrse drug- 
resistant phenotypes in ncoplastic cells that o\erenpress 
.\lI>Kl and \IKP and perhaps also other related rrans- 
portus, such as those implicated in drug resistance in 
infccrious tii\c;lscs. FE‘urtlier strumiT nianipul:ltion of 
lipicl-iiiodificd c)sIcinc con~po~~nds c0~1ld lead to the gen- 
eration of agents that arc highI> specific for each trans- 
I>orrer; such conipounds could ha\-c cnormoLis IISC in the 
1,1-c\-cntion of drug resistance in ;I \,ariet)- of pxhological 
condition\. 
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